PT1638969E - Antagonistas do receptor de cgrp - Google Patents

Antagonistas do receptor de cgrp Download PDF

Info

Publication number
PT1638969E
PT1638969E PT04749887T PT04749887T PT1638969E PT 1638969 E PT1638969 E PT 1638969E PT 04749887 T PT04749887 T PT 04749887T PT 04749887 T PT04749887 T PT 04749887T PT 1638969 E PT1638969 E PT 1638969E
Authority
PT
Portugal
Prior art keywords
receptor antagonists
cgrp receptor
cgrp
antagonists
receptor
Prior art date
Application number
PT04749887T
Other languages
English (en)
Inventor
Christopher S Burgey
Zhengwu J Deng
Diem N Nguyen
Daniel V Paone
Anthony W Shaw
Theresa M Williams
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PT1638969E publication Critical patent/PT1638969E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT04749887T 2003-04-15 2004-04-09 Antagonistas do receptor de cgrp PT1638969E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46308903P 2003-04-15 2003-04-15
US51035203P 2003-10-10 2003-10-10

Publications (1)

Publication Number Publication Date
PT1638969E true PT1638969E (pt) 2009-01-16

Family

ID=33303112

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04749887T PT1638969E (pt) 2003-04-15 2004-04-09 Antagonistas do receptor de cgrp

Country Status (33)

Country Link
US (6) US6953790B2 (pt)
EP (2) EP2039694B1 (pt)
JP (1) JP3967766B2 (pt)
KR (1) KR100769030B1 (pt)
CN (1) CN100384843C (pt)
AR (1) AR045887A1 (pt)
AT (1) ATE413400T1 (pt)
AU (1) AU2004230926B2 (pt)
BR (1) BRPI0409601A (pt)
CA (1) CA2522220C (pt)
CL (1) CL2004000788A1 (pt)
CO (1) CO5640130A2 (pt)
CY (1) CY1108714T1 (pt)
DE (1) DE602004017608D1 (pt)
DK (1) DK1638969T3 (pt)
EC (1) ECSP056097A (pt)
ES (1) ES2314417T3 (pt)
HK (1) HK1090922A1 (pt)
HR (1) HRP20080666T3 (pt)
IS (1) IS2759B (pt)
JO (1) JO2355B1 (pt)
MA (1) MA27728A1 (pt)
MX (1) MXPA05011166A (pt)
NO (1) NO327655B1 (pt)
NZ (1) NZ543357A (pt)
PE (1) PE20050020A1 (pt)
PL (1) PL1638969T3 (pt)
PT (1) PT1638969E (pt)
RU (1) RU2308458C2 (pt)
SI (1) SI1638969T1 (pt)
TW (1) TWI314931B (pt)
UA (1) UA82877C2 (pt)
WO (2) WO2004092166A2 (pt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US20040063735A1 (en) * 2002-06-05 2004-04-01 Chaturvedula Prasad V. Calcitonin gene related peptide receptor antagonists
JP4705908B2 (ja) * 2003-04-15 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体拮抗薬
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
AU2004252150B2 (en) * 2003-06-26 2008-11-20 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
CA2529196A1 (en) * 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
WO2005072308A2 (en) * 2004-01-29 2005-08-11 Merck & Co., Inc. Cgrp receptor antagonists
BRPI0507971A (pt) * 2004-02-23 2007-07-24 Tufts College composto, composição farmacêutica, uso de um composto,método para inibir a atividade proteolìtica de uma enzima de clivagem pós-prolina e remédio empacotado
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
CN101072771B (zh) * 2004-10-07 2010-09-29 默沙东公司 Cgrp受体拮抗剂
CA2583534A1 (en) 2004-10-14 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
CN101068595A (zh) * 2004-10-22 2007-11-07 默克公司 Cgrp受体拮抗剂
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB2467060B (en) * 2005-02-11 2010-09-01 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
GB2423085C (en) 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
US7994325B2 (en) 2005-03-14 2011-08-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
CN100371327C (zh) * 2005-11-17 2008-02-27 江苏工业学院 2-氨基-6-烷氧基-3-硝基吡啶的一步合成法
CA2629409A1 (en) * 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam aryl cgrp receptor antagonists
EP2007731B1 (en) * 2006-04-10 2009-07-22 Merck & Co., Inc. Process for the preparation of caprolactam cgrp antagonist intermediate
US20100286122A1 (en) * 2006-04-10 2010-11-11 Kevin Belyk CGRP Antagonist Salt
JP2009533439A (ja) * 2006-04-10 2009-09-17 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ拮抗薬の製造方法
CA2649158A1 (en) * 2006-04-10 2007-10-25 Merck & Co., Inc. Process for the preparation of pyridine heterocycle cgrp antagonist intermediate
ES2368456T3 (es) * 2006-05-02 2011-11-17 Bristol-Myers Squibb Company Compuestos restringidos como antagonistas del receptor de cgrp.
US7470680B2 (en) * 2006-05-03 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
KR20090018107A (ko) * 2006-05-09 2009-02-19 머크 앤드 캄파니 인코포레이티드 치환된 스피로사이클릭 ｃｇｒｐ 수용체 길항제
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
MX2008015906A (es) * 2006-06-13 2009-03-06 Vertex Pharma Antagonistas del receptor del peptido relacionado con el gen de calcitonina.
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
ES2558517T3 (es) * 2006-08-02 2016-02-04 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
JP2010502710A (ja) * 2006-09-08 2010-01-28 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ拮抗薬の経口投与のための液体医薬製剤
RU2470021C2 (ru) 2007-05-23 2012-12-20 Мерк Шарп Энд Домэ Корп. Пиридилпиперидиновые антагонисты рецептора орексинов
GB0712392D0 (en) * 2007-06-26 2007-08-01 Glaxo Group Ltd Novel compounds
US20090075977A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk0974
CA2722536A1 (en) 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
AU2009215731A1 (en) 2008-02-19 2009-08-27 Merck Sharp & Dohme Corp. Imidazobenzazepine CGRP receptor antagonists
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US20100009967A1 (en) * 2008-06-30 2010-01-14 Majid Mahjour Solid dosage formulations of telcagepant potassium
CA2739927A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
MX2012002464A (es) 2009-08-28 2012-03-14 Rinat Neuroscience Corp El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral.
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
TWI487706B (zh) 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
CA2830348A1 (en) * 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
AU2012258976B8 (en) 2011-05-20 2017-07-20 H. Lundbeck A/S Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
HUE054437T2 (hu) 2011-05-20 2021-09-28 H Lundbeck As Anti-CGRP készítmények és alkalmazásuk
EP2709663B1 (en) 2011-05-20 2019-03-20 AlderBio Holdings LLC Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EA028060B1 (ru) 2011-07-13 2017-10-31 Сайтокинетикс, Инк. Комбинированная терапия бокового амиотрофического склероза
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
EP3254681B1 (en) 2012-02-27 2019-06-19 Bristol-Myers Squibb Company N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt
US9375002B2 (en) 2012-03-29 2016-06-28 Bayer Intellectual Property Gmbh 5-aminopyrimidine derivatives and use thereof for combating undesired plant growth
EP3102564A4 (en) 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
GB201417707D0 (en) 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
CA3036632A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
CN111683937A (zh) 2018-01-19 2020-09-18 爱杜西亚药品有限公司 C5a受体调节剂
CN108892635A (zh) * 2018-09-07 2018-11-27 江苏工程职业技术学院 一种西沙必利关键中间体的制备方法
EP3908606A4 (en) 2019-01-08 2022-11-23 H. Lundbeck A/S ACUTE AND RAPID TREATMENT OF HEADACHES USING ANTI-CGRP ANTIBODIES
MX2023007575A (es) 2020-12-22 2023-09-21 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3212151A1 (en) 2021-03-02 2022-09-09 Cgrp Diagnostics Gmbh Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
JP2002525371A (ja) * 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
ES2203246T3 (es) 1998-09-30 2004-04-01 Taisho Pharmaceutical Co., Ltd Compuestos de isoxazoliltiofeno sustituidos.
US20040063735A1 (en) * 2002-06-05 2004-04-01 Chaturvedula Prasad V. Calcitonin gene related peptide receptor antagonists
JP4705908B2 (ja) * 2003-04-15 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体拮抗薬

Also Published As

Publication number Publication date
US20040229861A1 (en) 2004-11-18
WO2004092166A3 (en) 2005-01-20
TWI314931B (en) 2009-09-21
CN100384843C (zh) 2008-04-30
AU2004230926A1 (en) 2004-10-28
RU2308458C2 (ru) 2007-10-20
JP3967766B2 (ja) 2007-08-29
EP2039694A1 (en) 2009-03-25
HRP20080666T3 (en) 2009-01-31
IS2759B (is) 2011-10-15
AR045887A1 (es) 2005-11-16
HK1090922A1 (en) 2007-01-05
US7452903B2 (en) 2008-11-18
JP2006523697A (ja) 2006-10-19
CN1802376A (zh) 2006-07-12
PL1638969T3 (pl) 2009-04-30
US7772224B2 (en) 2010-08-10
CY1108714T1 (el) 2014-04-09
MA27728A1 (fr) 2006-01-02
KR100769030B1 (ko) 2007-10-22
NO327655B1 (no) 2009-09-07
BRPI0409601A (pt) 2006-04-18
EP1638969B1 (en) 2008-11-05
CO5640130A2 (es) 2006-05-31
RU2005135440A (ru) 2006-03-20
US20080280857A1 (en) 2008-11-13
EP2039694B1 (en) 2014-03-26
AU2004230926B2 (en) 2008-07-17
DK1638969T3 (da) 2009-01-26
NZ543357A (en) 2008-08-29
ES2314417T3 (es) 2009-03-16
ECSP056097A (es) 2006-03-01
WO2004092168A1 (en) 2004-10-28
DE602004017608D1 (de) 2008-12-18
MXPA05011166A (es) 2005-12-14
CA2522220A1 (en) 2004-10-28
WO2004092166A2 (en) 2004-10-28
US20090192139A1 (en) 2009-07-30
JO2355B1 (en) 2006-12-12
US20070225272A1 (en) 2007-09-27
PE20050020A1 (es) 2005-02-18
CL2004000788A1 (es) 2005-02-25
UA82877C2 (en) 2008-05-26
IS8055A (is) 2005-09-29
US7534784B2 (en) 2009-05-19
US7893052B2 (en) 2011-02-22
NO20055375L (no) 2005-11-14
CA2522220C (en) 2009-06-23
US20100298303A1 (en) 2010-11-25
US6953790B2 (en) 2005-10-11
TW200505903A (en) 2005-02-16
KR20050121734A (ko) 2005-12-27
SI1638969T1 (sl) 2009-02-28
ATE413400T1 (de) 2008-11-15
US20050256098A1 (en) 2005-11-17
US7235545B2 (en) 2007-06-26
EP1638969A2 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
HK1090922A1 (en) Cgrp receptor antagonists cgrp
EP1765805A4 (en) CGRP RECEPTOR ANTAGONISTS
IL174538A0 (en) Thrombin receptor antagonists
EP1641781A4 (en) BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS
EP1799672A4 (en) CGRP RECEPTOR ANTAGONIST
EP1814550A4 (en) ANTAGONISTS OF N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1
AU2003261392A8 (en) M3muscarinic acetylcholine receptor antagonists
TWI346553B (en) Chemokine receptor antagonists
IL172822A0 (en) Muscarnic acetylcholine receptor antagonists
TWI341198B (en) Hydroisoindoline tachykinin receptor antagonists
TWI348467B (en) Nk1 antagonists
ZA200702790B (en) Thrombin receptor antagonists
HK1070887A1 (en) Tricyclic thrombin receptor antagonists
IL175084A0 (en) Antagonists of the bradykinin b1 receptor
EP1912653A4 (en) Heterocyclic benzodiazepine-CGRP receptor antagonists
PL378753A1 (pl) Antagoniści receptora CCR-3
EP1812008A4 (en) ANTAGONISTS OF THE IL-8 RECEPTOR
EP1631559A4 (en) IL-8 SB / SB RECEPTOR ANTAGONISTS
EP1696949A4 (en) VEGF Receptor Antagonists
SG131946A1 (en) Ccr3 receptor antagonists
AU2003287219A8 (en) Il-8 receptor antagonists
ZA200605574B (en) Hydroisoindoline tachykinin receptor antagonists
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
GB0302094D0 (en) EP4 receptor antagonists
SI1534736T1 (sl) Antagonisti Nogo receptorja